Abbott Laboratories ROE 2006-2018 | ABT

Current and historical return on equity (ROE) values for Abbott Laboratories (ABT) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Abbott Laboratories ROE for the three months ending September 30, 2018 was 16.05%.
Abbott Laboratories ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-09-30 $0.89B $30.90B 2.85%
2018-06-30 $0.93B $30.77B 2.95%
2018-03-31 $0.48B $31.60B 1.50%
2017-12-31 $0.48B $31.10B 1.51%
2017-09-30 $2.10B $32.22B 7.23%
2017-06-30 $1.17B $31.79B 4.46%
2017-03-31 $1.50B $31.55B 6.40%
2016-12-31 $1.40B $20.72B 6.73%
2016-09-30 $1.37B $20.90B 6.53%
2016-06-30 $2.28B $20.80B 10.82%
2016-03-31 $2.45B $20.84B 11.31%
2015-12-31 $4.42B $21.33B 20.18%
2015-09-30 $4.56B $21.22B 20.74%
2015-06-30 $4.52B $23.13B 20.14%
2015-03-31 $4.20B $21.99B 18.60%
2014-12-31 $2.28B $21.64B 9.95%
2014-09-30 $1.97B $22.99B 8.25%
2014-06-30 $2.40B $23.70B 9.96%
2014-03-31 $2.41B $23.49B 10.14%
2013-12-31 $2.58B $25.27B 10.94%
2013-09-30 $3.04B $23.79B 12.70%
2013-06-30 $4.02B $22.43B 16.22%
2013-03-31 $5.27B $22.68B 20.82%
2012-12-31 $5.96B $26.81B 22.93%
2012-09-30 $6.53B $27.10B 25.67%
2012-06-30 $4.89B $24.57B 19.69%
2012-03-31 $5.11B $25.54B 20.18%
2011-12-31 $4.73B $24.53B 18.84%
2011-09-30 $4.55B $24.69B 18.45%
2011-06-30 $5.14B $26.47B 21.54%
2011-03-31 $4.49B $24.72B 20.18%
2010-12-31 $4.63B $22.77B 21.71%
2010-09-30 $4.73B $21.48B 22.06%
2010-06-30 $5.31B $20.00B 24.84%
2010-03-31 $5.31B $21.01B 24.84%
2009-12-31 $5.75B $23.19B 27.87%
2009-09-30 $5.74B $21.38B 29.91%
2009-06-30 $5.35B $19.92B 28.61%
2009-03-31 $5.38B $17.98B 29.17%
2008-12-31 $4.88B $17.52B 26.45%
2008-09-30 $4.55B $19.35B 24.55%
2008-06-30 $4.18B $18.96B 23.76%
2008-03-31 $3.85B $17.98B 23.05%
2007-12-31 $3.61B $17.82B 22.87%
2007-09-30 $1.93B $15.61B 13.00%
2007-06-30 $1.93B $15.33B 12.99%
2007-03-31 $1.55B $14.32B 10.47%
2006-12-31 $1.72B $14.05B 11.58%
2006-09-30 $3.17B $15.63B 21.24%
2006-06-30 $3.13B $15.19B 21.50%
2006-03-31 $3.40B $14.44B 23.64%
2005-12-31 $3.37B $14.42B 23.56%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $126.526B $27.390B
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $126.543B 19.40
Stryker (SYK) United States $64.420B 24.28
Boston Scientific (BSX) United States $51.491B 26.02
Baxter (BAX) United States $35.393B 22.86
Zimmer Biomet Holdings (ZBH) United States $23.875B 15.48
Smith & Nephew SNATS (SNN) United Kingdom $16.038B 0.00
ResMed (RMD) United States $14.846B 28.31
Perrigo (PRGO) Ireland $8.596B 13.05
Bio-Rad Laboratories (BIO) United States $8.274B 52.91
Canopy Growth (CGC) Canada $8.174B 0.00
Hill-Rom Holdings (HRC) United States $6.270B 19.88
Aurora Cannabis (ACB) Canada $6.172B 33.68
Haemonetics (HAE) United States $5.727B 50.36
ICU Medical (ICUI) United States $4.968B 27.68
Insulet (PODD) United States $4.838B 0.00
Agios Pharmaceuticals (AGIO) United States $4.052B 0.00
Hutchison China MediTech (HCM) China $4.010B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $3.990B 0.00
Neogen (NEOG) United States $3.294B 49.88
NuVasive (NUVA) United States $3.166B 29.46
National Vision Holdings (EYE) United States $3.024B 58.49
Quidel (QDEL) United States $2.507B 32.68
Aphria (APHA) $2.433B 0.00
NxStage Medical (NXTM) United States $1.933B 0.00
Phibro Animal Health (PAHC) United States $1.409B 19.95
AtriCure (ATRC) United States $1.241B 0.00
Cardiovascular Systems (CSII) United States $1.058B 1524.50
VAREX IMAGING (VREX) United States $0.999B 20.07
Meridian Bioscience (VIVO) United States $0.823B 26.23
Surmodics (SRDX) United States $0.794B 121.41
OraSure Technologies (OSUR) United States $0.772B 43.48
Eagle Pharmaceuticals (EGRX) United States $0.756B 24.24
MacroGenics (MGNX) United States $0.740B 0.00
Cerus (CERS) United States $0.716B 0.00
PetIQ (PETQ) United States $0.705B 20.03
Lantheus Holdings (LNTH) United States $0.625B 19.34
Omeros (OMER) United States $0.619B 0.00
LeMaitre Vascular (LMAT) United States $0.540B 26.52
Owens & Minor (OMI) United States $0.535B 6.05
Insys Therapeutics (INSY) United States $0.527B 0.00
NanoString Technologies (NSTG) United States $0.521B 0.00
TG Therapeutics (TGTX) United States $0.444B 0.00
Evolus (EOLS) United States $0.403B 0.00
Quanterix (QTRX) United States $0.376B 0.00
Utah Medical Products (UTMD) United States $0.332B 21.45
Cytosorbents (CTSO) United States $0.313B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.264B 0.00
Surface Oncology (SURF) United States $0.225B 0.00
Rockwell Medical (RMTI) United States $0.214B 0.00
BioLife Solutions (BLFS) United States $0.204B 275.00
Chimerix (CMRX) United States $0.172B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.146B 0.00
Fonar (FONR) United States $0.141B 7.06
Imprimis Pharmaceuticals (IMMY) United States $0.123B 0.00
Chembio Diagnostics (CEMI) United States $0.106B 0.00
United-Guardian (UG) United States $0.080B 16.85
Female Health (VERU) United States $0.075B 0.00
Oramed Pharmaceuticals (ORMP) Israel $0.070B 0.00
Trinity Biotech (TRIB) Ireland $0.066B 21.07
CAS Medical Systems (CASM) United States $0.053B 0.00
Neurotrope (NTRP) United States $0.048B 0.00
ImmuCell (ICCC) United States $0.043B 0.00
Capricor Therapeutics (CAPR) United States $0.029B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.018B 0.00
Senestech (SNES) United States $0.017B 0.00
Akers Biosciences Inc (AKER) United States $0.015B 0.00
Cellectar Biosciences (CLRB) United States $0.011B 0.00
Valeritas Holdings (VLRX) United States $0.010B 0.00
NeuroMetrix (NURO) United States $0.008B 0.00